[ad_1]
“This vaccine has not been registered in any country of the European Union or EMA (European Medicines Agency – 15 min) he definitely hasn’t evaluated it, ”I. Šimonytė said during a remote press conference on Friday.
Josep Borrell, head of diplomacy for the European Union, who visited Moscow on Friday morning, expressed his hope that the COVID-19 vaccine, developed in Russia, will soon be used throughout the Community of 27 Member States and confirmed by the European Medicines Agency.
When asked if Lithuania would buy the Sputnik V vaccine in this case, I. Šimonytė replied:
“I’m sorry, but I can’t make assumptions because the EMA decides which vaccine should be approved, not Mr. Borell.”
“There will be no more comment on this topic than I did, because Sputnik V is certainly not the vaccine that we have included in our vaccine portfolio,” he added.
The Russian government approved a domestic vaccine against COVID-19 in August.
The vaccine was initially criticized for its haste to develop and a lack of transparent information.
However, a comprehensive study by Russian scientists recently appeared in the British scientific journal Lancet, the results of which are not in doubt by independent experts.
“Reuters” / “Scanpix” / “Companion V” vaccine
It is reported here that the effectiveness of the Russian vaccine, based on clinical trials, is 91%, and those still infected with COVID-19 are more likely to become ill after vaccination.
More about the study and the Sputnik V vaccine against COVID-19 – here.
The use of the Sputnik V vaccine was provisionally approved by Hungary at the end of January, but will ultimately be decided by the Hungarian Public Health Center.
Vaccination with a Russian-developed vaccine in Hungary is scheduled to begin next week.
Final checks on the vaccine are currently underway, according to Hungarian Prime Minister Viktor Orban.
[ad_2]
